SEOUL, Feb. 27 (Yonhap) — A group of 300 medical workers treating novel coronavirus patients started receiving the first batch of the vaccine developed by U.S. pharmaceutical giant Pfizer Inc. in South Korea on Saturday, one day after the country kicked off a free vaccination campaign.
Doctors, nurses and other health professionals treating COVID-19 patients in the greater Seoul area were administered with their first shots of Pfizer’s two-dose vaccine regimen at a state-run vaccination facility in central Seoul.
The inoculation comes a day after the country started its public inoculation program.
Health care workers and patients aged under 65 at long-term care facilities began receiving the first shots of the two-dose vaccine regimen developed by British-Swedish pharmaceutical giant AstraZeneca and Oxford University.
A total of 55,000 medical workers at hospitals for virus patients will receive Pfizer vaccines, which are part of the World Health Organization’s global vaccine COVAX Facility project.
Pfizer shots will first be administered at five state-run vaccination facilities in the wider Seoul area as the products require ultra-cold conditions. The authorities plan to build 120 such facilities at general hospitals, gymnasiums and other kinds of government sites.
Health authorities plan to complete inoculations with the first batch of Pfizer products by March 20.
Authorities, meanwhile, added they are currently working to vaccinate seven people per bottle, which is higher than the previous estimate of six.
The National Medical Center said they are seeking to maximize the number of recipients by utilizing “low dead space (LDS)” syringes designed to minimize wasted vaccine doses by reducing space between the needle and the plunger when fully pushed in.
If successful, it would mark the first case in the world to do so.
The center said it will closely monitor the vaccination process and report the result in the near future.
Earlier, the U.S. Food and Drug Administration said it will allow the Pfizer vaccine to be transported and stored for up to two weeks at conventional freezer temperatures instead of the ultra-cold conditions.
Seoul’s drug authorities, however, said they have not yet reviewed whether to allow storing the Pfizer vaccine at higher temperatures, citing that further data is needed for the review.
Another 10 million doses of Pfizer products under a direct contract between the pharmaceutical firm and the Seoul government are expected to arrive here in the third quarter.